[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Liquid Biopsy Market Size, Share & Trends Analysis Report By Biomarker (Exosomes, CTC), By Technology (NGS, PCR Microarrays), By Sample Type, By Region (APAC, North America), And Segment Forecasts, 2021 - 2028

October 2021 | 180 pages | ID: L3FDC94752CEN
Grand View Research, Inc.

US$ 5,950.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 72 Business Hours

Liquid Biopsy Market Growth & Trends

The global liquid biopsy market size is expected to reach USD 19.35 billion by 2028, registering a CAGR of 13.5% during the forecast period, according to a new report by Grand View Research, Inc. It is a revolutionary technique that has created various opportunities that were previously unexplored.

It aids in the detection and isolation of circulating tumor DNA, exosomes, and circulating tumor cells and is a source of proteomics and genomics information in cancer patients. Rapid development in digital Polymerase Chain Reaction (PCR) and NGS-based technology has improved the accuracy of liquid biopsy. It can be performed repeatedly for disease monitoring and is anticipated to help overcome the limitations of tissue biopsies.

As liquid biopsies are the most promising novel techniques for cancer care, established as well as emerging companies have increased their R&D to develop novel liquid biopsy solutions. For instance, in September 2021, AnchorDx Medical Co., Ltd.; a China-based developer of early cancer detection and oncology screening solutions developed a diagnostic model for early breast cancer detection. The model is based on the methylation patterns of cfDNA.

Liquid Biopsy Market Report Highlights
  • The Multi-gene Parallel Analysis (NGS) technology segment held the largest revenue share of the global market in 2020
  • This can be attributed to rapid enhancements in NGS technology. With this technology, liquid biopsies are anticipated to gain considerable importance in cancer-related studies and research
  • On the basis of sample type, blood sample-based tests dominated the market in 2020
  • Blood samples can readily be taken at a more frequent interval, thus increasing the adoption rate
  • Circulating Nucleic Acids are the most commonly used biomarker for liquid biopsy tests
  • The factors, such as the constantly evolving pipeline of ctDNA-based liquid biopsy tests, an increasing number of commercialized products, and the potential of ctRNA in determining molecular profile have contributed to the dominance of this segment
  • North America is expected to be the largest revenue-generating region by 2028 owing to a high incidence of cancer, rapid technological advancements, and the presence of key players in the region
  • Key players are focused on business expansion through product launches, mergers & acquisitions, agreements, partnerships, and other growth strategies
  • For instance, in June 2021, Biocept, Inc. collaborated with Quest Diagnostics to provide advanced NGS-based liquid biopsy testing for lung cancer patients
CHAPTER 1 METHODOLOGY AND SCOPE

1.1 Research Assumptions
1.2 Research Methodology
1.3 Information Procurement
  1.3.1 Sample size for the study on liquid biopsy market:
    1.3.1.1 Primary Sources:
    1.3.1.2 Secondary Data Sources:
1.4 Information or Data Analysis
1.5 Market Formulation & Validation
1.6 Global Market: CAGR Calculation
1.7 Objectives
  1.7.1 Objective 1:
  1.7.2 Objective 2:

CHAPTER 2 EXECUTIVE SUMMARY

2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Milieu
2.4 Market Summary, 2020

CHAPTER 3 INDUSTRY OUTLOOK

3.1 Market Segmentation& Scope
3.2 Penetration and Growth Prospect Mapping for Biomarker, 2020 (USD Million)
3.3 COVID-19 Impact Analysis
3.4 Liquid Biopsy Pipeline Analysis
3.5 Liquid Biopsy Pricing Analysis
3.6 Liquid Biopsy Procedure Analysis
3.7 Business Environment Analysis
  3.7.1 SWOT Analysis; By factor (Political & Legal, Economic, and Technological)
  3.7.2 Porter’s Five Forces Analysis

CHAPTER 4 MARKET DYNAMICS

4.1 Market Dynamics
  4.1.1 Market Driver Analysis
    4.1.1.1 Technological Advancements In Cancer Diagnostics To Reduce Complications Associated With Conventional Means Of Cancer Detection
    4.1.1.2 Rising Preference For Minimally Invasive Form Of Cancer Diagnostics
    4.1.1.3 Increase In Number Of Ongoing Trials For Development Of Liquid Biopsy Assays And Tests
  4.1.2 Market restraint analysis
    4.1.2.1 Low Abundance And Fragility Of Circulating Tumor Cells
    4.1.2.2 Availability Of Other Genomic Tests For Cancer Diagnostics And Treatment
4.2 Market Deals & Strategic Alliances Analysis

CHAPTER 5 TECHNOLOGY BUSINESS ANALYSIS

5.1 Liquid Biopsy Market: Technology Movement Analysis
5.2 Multi-Gene-Parallel Analysis (NGS)
  5.2.1 Global liquid biopsy Multi-Gene-Parallel Analysis (NGS)technology market estimates and forecast, 2017 - 2028 (USD Million)
5.3 Single Gene Analysis (PCR Microarrays)
  5.3.1 Global liquid biopsy Single Gene Analysis (PCR Microarrays)technology market estimates and forecast, 2017 - 2028 (USD Million)

CHAPTER 6 SAMPLE TYPE BUSINESS ANALYSIS

6.1 Liquid Biopsy Market: Sample Type Movement Analysis
6.2 Blood Sample Based
  6.2.1 Blood sample based Liquid biopsy market estimates and forecast, 2017 - 2028 (USD Million)
6.3 Other Samples
  6.3.1 Other samples based Liquid biopsy market for other products & services, 2017 - 2028 (USD Million)

CHAPTER 7 BIOMARKER BUSINESS ANALYSIS

7.1 Liquid Biopsy Market: Biomarker Movement Analysis
7.2 Circulating Nucleic Acids
  7.2.1 Global Circulating Nucleic Acids based Liquid biopsy market, 2017 - 2028 (USD Million)
7.3 Circulating Tumor Cells (CTCs)
  7.3.1 Global circulating tumor cells (CTC) based Liquid biopsy market, 2017 - 2028 (USD Million)
7.4 Exosomes/Microvesicles
  7.4.1 Global Exosomes/Microvesicles based Liquid biopsy market for health care end use, 2017 - 2028 (USD Million)
7.5 Circulating Proteins
  7.5.1 Global Circulating Proteins based Liquid biopsy market for industry end use, 2017 - 2028 (USD Million)

CHAPTER 8 REGIONAL BUSINESS ANALYSIS

8.1 Liquid Biopsy Market: Regional Movement Analysis
8.2 North America
  8.2.1 North America Liquid biopsy market, 2017 - 2028 (USD Million)
  8.2.2 U.S.
    8.2.2.1 U.S. Liquid biopsy market, 2017 - 2028 (USD Million)
    8.2.2.2 U.S. Liquid biopsy market, by sample type, 2017 - 2028 (USD Million)
    8.2.2.3 U.S. Liquid biopsy market, by biomarker, 2017 - 2028 (USD Million)
    8.2.2.4 U.S. Liquid biopsy market, by technology, 2017 - 2028 (USD Million)
  8.2.3 Canada
    8.2.3.1 Canada Liquid biopsy market, 2017 - 2028 (USD Million)
    8.2.3.2 Canada Liquid biopsy market, by sample type, 2017 - 2028 (USD Million)
    8.2.3.3 Canada Liquid biopsy market, by biomarker, 2017 - 2028 (USD Million)
    8.2.3.4 Canada Liquid biopsy market, by technology, 2017 - 2028 (USD Million)
8.3 Europe
  8.3.1 Europe Liquid biopsy market, 2017 - 2028 (USD Million)
  8.3.2 Germany
    8.3.2.1 Germany Liquid biopsy market, 2017 - 2028 (USD Million)
    8.3.2.2 Germany Liquid biopsy market, by sample type, 2017 - 2028 (USD Million)
    8.3.2.3 Germany Liquid biopsy market, by biomarker, 2017 - 2028 (USD Million)
    8.3.2.4 Germany Liquid biopsy market, by technology, 2017 - 2028 (USD Million)
  8.3.3 U.K.
    8.3.3.1 U.K. Liquid biopsy market, 2017 - 2028 (USD Million)
    8.3.3.2 U.K. Liquid biopsy market, by sample type, 2017 - 2028 (USD Million)
    8.3.3.3 U.K. Liquid biopsy market, by biomarker, 2017 - 2028 (USD Million)
    8.3.3.4 U.K. Liquid biopsy market, by technology, 2017 - 2028 (USD Million)
8.4 Asia-Pacific
  8.4.1 Asia Pacific Liquid biopsy market, 2017 - 2028 (USD Million)
  8.4.2 Japan
    8.4.2.1 Japan Liquid biopsy market, 2017 - 2028 (USD Million)
    8.4.2.2 Japan Liquid biopsy market, by sample type, 2017 - 2028 (USD Million)
    8.4.2.3 Japan Liquid biopsy market, by biomarker, 2017 - 2028 (USD Million)
    8.4.2.4 Japan Liquid biopsy market, by technology, 2017 - 2028 (USD Million)
  8.4.3 China
    8.4.3.1 China Liquid biopsy market, 2017 - 2028 (USD Million)
    8.4.3.2 China Liquid biopsy market, by sample type, 2017 - 2028 (USD Million)
    8.4.3.3 China Liquid biopsy market, by biomarker, 2017 - 2028 (USD Million)
    8.4.3.4 China Liquid biopsy market, by technology, 2017 - 2028 (USD Million)
  8.4.4 India
    8.4.4.1 India Liquid biopsy market, 2017 - 2028 (USD Million)
    8.4.4.2 India Liquid biopsy market, by sample type, 2017 - 2028 (USD Million)
    8.4.4.3 India Liquid biopsy market, by biomarker, 2017 - 2028 (USD Million)
    8.4.4.4 India Liquid biopsy market, by technology, 2017 - 2028 (USD Million)
8.5 Latin America
  8.5.1 Latin America Liquid biopsy market, 2017 - 2028 (USD Million)
  8.5.2 Brazil
    8.5.2.1 Brazil Liquid biopsy market, 2017 - 2028 (USD Million)
    8.5.2.2 Brazil Liquid biopsy market, by sample type, 2017 - 2028 (USD Million)
    8.5.2.3 Brazil Liquid biopsy market, by biomarker, 2017 - 2028 (USD Million)
    8.5.2.4 Brazil Liquid biopsy market, by technology, 2017 - 2028 (USD Million)
  8.5.3 Mexico
    8.5.3.1 Mexico Liquid biopsy market, 2017 - 2028 (USD Million)
    8.5.3.2 Mexico Liquid biopsy market, by sample type, 2017 - 2028 (USD Million)
    8.5.3.3 Mexico Liquid biopsy market, by biomarker, 2017 - 2028 (USD Million)
    8.5.3.4 Mexico Liquid biopsy market, by technology, 2017 - 2028 (USD Million)
8.6 MEA
  8.6.1 Middle East Africa Liquid biopsy market, 2017 - 2028 (USD Million)
  8.6.2 South Africa
    8.6.2.1 South Africa Liquid biopsy market, 2017 - 2028 (USD Million)
    8.6.2.2 South Africa Liquid biopsy market, by sample type, 2017 - 2028 (USD Million)
    8.6.2.3 South Africa Liquid biopsy market, by biomarker, 2017 - 2028 (USD Million)
    8.6.2.4 South Africa Liquid biopsy market, by technology, 2017 - 2028 (USD Million)

CHAPTER 9 COMPETITIVE LANDSCAPE

9.1 Company Profiles
  9.1.1 QIAGEN
    9.1.1.1 Company overview
    9.1.1.2 Financial Performance
    9.1.1.3 Product benchmarking
    9.1.1.4 Strategic initiatives
  9.1.2 Myriad Genetics, Inc.
    9.1.2.1 Company overview
    9.1.2.2 Financial Performance
    9.1.2.3 Product benchmarking
    9.1.2.4 Strategic initiatives
  9.1.3 BIOCEPT, inc.
    9.1.3.1 Company overview
    9.1.3.2 Financial Performance
    9.1.3.3 Product benchmarking
    9.1.3.4 Strategic initiatives
  9.1.4 Guardant Health, Inc.
    9.1.4.1 Company overview
    9.1.4.2 Financial Performance
    9.1.4.3 Product benchmarking
    9.1.4.4 Strategic initiatives
  9.1.5 F. Hoffmann-La Roche Ltd.
    9.1.5.1 Company overview
    9.1.5.2 Financial Performance
    9.1.5.3 Product benchmarking
    9.1.5.4 Strategic initiatives
  9.1.6 Illumina, Inc.
    9.1.6.1 Company overview
    9.1.6.2 Grail Inc.
    9.1.6.3 Financial Performance
    9.1.6.4 Product benchmarking: Illumina Inc.
    9.1.6.5 Product benchmarking: Grail Inc.
    9.1.6.6 Strategic initiatives
  9.1.7 Angle plc
    9.1.7.1 Company overview
    9.1.7.2 Financial Performance
    9.1.7.3 Product benchmarking
    9.1.7.4 Strategic initiatives
  9.1.8 Oncimmune
    9.1.8.1 Company overview
    9.1.8.2 Financial Performance
    9.1.8.3 Product benchmarking
  9.1.9 THERMO FISHER SCIENTIFIC, INC.
    9.1.9.1 Company Overview
    9.1.9.2 Financial Performance
    9.1.9.3 Product benchmarking
    9.1.9.4 Strategic initiatives
  9.1.10 LUCENCE HEALTH INC.
    9.1.10.1 Company Overview
    9.1.10.2 Product benchmarking
    9.1.10.3 Strategic initiatives
  9.1.11 FREENOME HOLDINGS, INC.
    9.1.11.1 Company Overview
    9.1.11.2 Product benchmarking
    9.1.11.3 Strategic initiatives
  9.1.12 EPIGENOMICS AG
    9.1.12.1 Company Overview
    9.1.12.2 Financial Performance
    9.1.12.3 Product benchmarking
    9.1.12.4 Strategic initiatives

LIST OF TABLES

Table 1 Liquid biopsy pipeline analysis
Table 2 Liquid biopsy pricing analysis
Table 3 Global Liquid Biopsy Market Segmentation
Table 4 List of software parameters to be optimized for cfDNA analysis by NGS
Table 5 The future potential of ctDNA and liquid biopsy in cancer
Table 6 Some ctRNAs as a biomarker in non-small cell lung cancer
Table 7 CTC enrichment technologies
Table 8 Comparison of the current exosomes isolation methods
Table 9 North America Liquid Biopsy Market, by Region, 2017 - 2028 (USD Million)
Table 10 North America Liquid Biopsy Market, by Sample Type, 2017 - 2028 (USD Million)
Table 11 North America Liquid Biopsy Market, by Biomarker, 2017 - 2028 (USD Million)
Table 12 North America Liquid Biopsy Market, by Technology, 2017 - 2028 (USD Million)
Table 13 U.S. Liquid Biopsy Market, by Region, 2017 - 2028 (USD Million)
Table 14 U.S. Liquid Biopsy Market, by Sample Type, 2017 - 2028 (USD Million)
Table 15 U.S. Liquid Biopsy Market, by Biomarker, 2017 - 2028 (USD Million)
Table 16 U.S. Liquid Biopsy Market, by Technology, 2017 - 2028 (USD Million)
Table 17 Canada Liquid Biopsy Market, by Region, 2017 - 2028 (USD Million)
Table 18 Canada Liquid Biopsy Market, by Sample Type, 2017 - 2028 (USD Million)
Table 19 Canada Liquid Biopsy Market, by Biomarker, 2017 - 2028 (USD Million)
Table 20 Canada Liquid Biopsy Market, by Technology, 2017 - 2028 (USD Million)
Table 21 Europe Liquid Biopsy Market, by Region, 2017 - 2028 (USD Million)
Table 22 Europe Liquid Biopsy Market, by Sample Type, 2017 - 2028 (USD Million)
Table 23 Europe Liquid Biopsy Market, by Biomarker, 2017 - 2028 (USD Million)
Table 24 Europe Liquid Biopsy Market, by Technology, 2017 - 2028 (USD Million)
Table 25 Germany Liquid Biopsy Market, by Region, 2017 - 2028 (USD Million)
Table 26 Germany Liquid Biopsy Market, by Sample Type, 2017 - 2028 (USD Million)
Table 27 Germany Liquid Biopsy Market, by Biomarker, 2017 - 2028 (USD Million)
Table 28 Germany Liquid Biopsy Market, by Technology, 2017 - 2028 (USD Million)
Table 29 U.K. Liquid Biopsy Market, by Region, 2017 - 2028 (USD Million)
Table 30 U.K. Liquid Biopsy Market, by Sample Type, 2017 - 2028 (USD Million)
Table 31 U.K. Liquid Biopsy Market, by Biomarker, 2017 - 2028 (USD Million)
Table 32 U.K. Liquid Biopsy Market, by Technology, 2017 - 2028 (USD Million)
Table 33 Asia Pacific Liquid Biopsy Market, by Region, 2017 - 2028 (USD Million)
Table 34 Asia Pacific Liquid Biopsy Market, by Sample Type, 2017 - 2028 (USD Million)
Table 35 Asia Pacific Liquid Biopsy Market, by Biomarker, 2017 - 2028 (USD Million)
Table 36 Asia Pacific Liquid Biopsy Market, by Technology, 2017 - 2028 (USD Million)
Table 37 Japan Liquid Biopsy Market, by Region, 2017 - 2028 (USD Million)
Table 38 Japan Liquid Biopsy Market, by Sample Type, 2017 - 2028 (USD Million)
Table 39 Japan Liquid Biopsy Market, by Biomarker, 2017 - 2028 (USD Million)
Table 40 Japan Liquid Biopsy Market, by Technology, 2017 - 2028 (USD Million)
Table 41 China Liquid Biopsy Market, by Region, 2017 - 2028 (USD Million)
Table 42 China Liquid Biopsy Market, by Sample Type, 2017 - 2028 (USD Million)
Table 43 China Liquid Biopsy Market, by Biomarker, 2017 - 2028 (USD Million)
Table 44 China Liquid Biopsy Market, by Technology, 2017 - 2028 (USD Million)
Table 45 India Liquid Biopsy Market, by Region, 2017 - 2028 (USD Million)
Table 46 India Liquid Biopsy Market, by Sample Type, 2017 - 2028 (USD Million)
Table 47 India Liquid Biopsy Market, by Biomarker, 2017 - 2028 (USD Million)
Table 48 India Liquid Biopsy Market, by Technology, 2017 - 2028 (USD Million)
Table 49 Latin America Liquid Biopsy Market, by Region, 2017 - 2028 (USD Million)
Table 50 Latin America Liquid Biopsy Market, by Sample Type, 2017 - 2028 (USD Million)
Table 51 Latin America Liquid Biopsy Market, by Biomarker, 2017 - 2028 (USD Million)
Table 52 Latin America Liquid Biopsy Market, by Technology, 2017 - 2028 (USD Million)
Table 53 Brazil Liquid Biopsy Market, by Region, 2017 - 2028 (USD Million)
Table 54 Brazil Liquid Biopsy Market, by Sample Type, 2017 - 2028 (USD Million)
Table 55 Brazil Liquid Biopsy Market, by Biomarker, 2017 - 2028 (USD Million)
Table 56 Brazil Liquid Biopsy Market, by Technology, 2017 - 2028 (USD Million)
Table 57 Mexico Liquid Biopsy Market, by Region, 2017 - 2028 (USD Million)
Table 58 Mexico Liquid Biopsy Market, by Sample Type, 2017 - 2028 (USD Million)
Table 59 Mexico Liquid Biopsy Market, by Biomarker, 2017 - 2028 (USD Million)
Table 60 Mexico Liquid Biopsy Market, by Technology, 2017 - 2028 (USD Million)
Table 61 MEA Liquid Biopsy Market, by Region, 2017 - 2028 (USD Million)
Table 62 MEA Liquid Biopsy Market, by Sample Type, 2017 - 2028 (USD Million)
Table 63 MEA Liquid Biopsy Market, by Biomarker, 2017 - 2028 (USD Million)
Table 64 MEA Liquid Biopsy Market, by Technology, 2017 - 2028 (USD Million)
Table 65 South Africa Liquid Biopsy Market, by Region, 2017 - 2028 (USD Million)
Table 66 South Africa Liquid Biopsy Market, by Sample Type, 2017 - 2028 (USD Million)
Table 67 South Africa Liquid Biopsy Market, by Biomarker, 2017 - 2028 (USD Million)
Table 68 South Africa Liquid Biopsy Market, by Technology, 2017 - 2028 (USD Million)
LIST OF FIGURES

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Liquid biopsy market snapshot, 2020 (USD Million)
Fig. 9 Liquid biopsy market segmentation
Fig. 10 Penetration and growth prospect mapping, 2020
Fig. 11 SWOT Analysis, By Factor (Political & legal, economic, and technological)
Fig. 12 Porter’s Five Forces Analysis
Fig. 13 Liquid biopsy market: Technology outlook and key takeaways
Fig. 14 Liquid biopsy market : Technology movement analysis
Fig. 15 Global liquid biopsy multi-gene-parallel analysis (NGS) technology market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 16 Global liquid biopsy single gene analysis (PCR microarrays) technology market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 17 Liquid biopsy market : Sample type outlook and key takeaways
Fig. 18 Liquid biopsy market : Sample type movement analysis
Fig. 19 Blood sample based liquid biopsy market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 20 Other samples based liquid biopsy market for other products & services, 2017 - 2028 (USD Million)
Fig. 21 Liquid biopsy market : Biomarker outlook and key takeaways
Fig. 22 Liquid biopsy market : Biomarker movement analysis
Fig. 23 Global circulating nucleic acids based liquid biopsy market, 2017 - 2028 (USD Million)
Fig. 24 Global circulating tumor cells (CTC) based liquid biopsy market, 2017 - 2028 (USD Million)
Fig. 25 Global exosomes/microvesicles based liquid biopsy market for healthcare end use, 2017 - 2028 (USD Million)
Fig. 26 Global circulating proteins based liquid biopsy market for industry end use, 2017 - 2028 (USD Million)
Fig. 27 Liquid biopsy market : Regional outlook and key takeaways
Fig. 28 Liquid biopsy market : Regional movement analysis
Fig. 29 North America liquid biopsy market, 2017 - 2028 (USD Million)
Fig. 30 U.S. liquid biopsy market, 2017 - 2028 (USD Million)
Fig. 31 Canada liquid biopsy market, 2017 - 2028 (USD Million)
Fig. 32 Europe liquid biopsy market, 2017 - 2028 (USD Million)
Fig. 33 Germany liquid biopsy market, 2017 - 2028 (USD Million)
Fig. 34 U.K. liquid biopsy market, 2017 - 2028 (USD Million)
Fig. 35 Asia Pacific liquid biopsy market, 2017 - 2028 (USD Million)
Fig. 36 Japan liquid biopsy market, 2017 - 2028 (USD Million)
Fig. 37 China liquid biopsy market, 2017 - 2028 (USD Million)
Fig. 38 India liquid biopsy market, 2017 - 2028 (USD Million)
Fig. 39 Latin America liquid biopsy market, 2017 - 2028 (USD Million)
Fig. 40 Brazil liquid biopsy market, 2017 - 2028 (USD Million)
Fig. 41 Mexico liquid biopsy market, 2017 - 2028 (USD Million)
Fig. 42 Middle East Africa liquid biopsy market, 2017 - 2028 (USD Million)
Fig. 43 South Africa liquid biopsy market, 2017 - 2028 (USD Million)


More Publications